NCT02199665: Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)

Multiple Myeloma Research Consortium

NCT02199665: Phase 1: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)

Seli-Kd

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)

This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for multiple myeloma.

Sponsor:

University of Chicago

Collaborator:

National Cancer Institute (NCI)

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT02199665

Official Title: A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

First Posted: July 24, 2014

Click here to see details on ClinicalTrials.gov

---

Drug: selinexor

Drug: carfilzomib

Drug: dexamethasone

---

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Br J Haematol; 2019

https://pubmed.ncbi.nlm.nih.gov/31124580/

---

Locations

United States, Arizona

United States, Illinois

United States, Michigan

United States, New York